louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00745355: Quality of Life in Patients With Bladder Cancer
Official title: A Prospective Study of Quality of Life in Patients With Bladder Cancer
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Bladder Cancer
Keywords: Quality of Life
Questionnaires
08-076
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: Albert Einstein College of Medicine
name: Northwell Health
name: Lenox Hill Hospital
name: DeltaQuest Foundation, Inc.
name: Lahey Hospital & Medical Center
First posted: 2008-09-03
Enrollment: 550
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All eligible MSKCC patients.

Brief summary: The purpose of this study is to learn about the quality of life of people living with bladder cancer. We are interested in learning about how the treatments for bladder cancer affect people. We plan to use the findings from this study to help doctors provide better care and information to patients with bladder cancer.


Eligibility criteria: Inclusion Criteria:

* All patients (male and female) who are diagnosed with bladder cancer
* Patients must be scheduled for radical cystectomy and urinary diversion are and/or being evaluated for neo-adjuvant chemotherapy prior to a planned cystectomy.
* Participants must be able to speak English.
* Participants must be able to provide informed consent.
* Participants must be 18 years of age or older to enroll.
* Participant may be eligible for and may receive neoadjuvant or adjuvant chemotherapy.
* Participant may have had intravesicle chemotherapy or immunotherapy (BCG, Interferon).

Exclusion Criteria:

* Subjects may be excluded from the study based on the following criteria:
* Follow-up care not obtained at MSKCC.
* Metastatic disease at diagnosis.

Primary outcomes:
measure: Prospectively characterize the impact of radical cystectomy and different urinary diversions on quality of life of bladder cancer patients.
timeFrame: conclusion of study
Secondary outcomes:
measure: Compare various standard and idiographic measures of QOL, to determine their relative contributions in accounting for variance in key outcome criteria and prediction of patient QOL at subsequent assessment points.
timeFrame: conclusion of study
measure: Examine how patients react to more in-depth probing of the interview associated with idiographic assessment.
timeFrame: conclusion of study
measure: Develop a predictive model of QOL after radical cystectomy & urinary diversion using the data from idiographic and standard QOL measures. This model can ultimately be used in office based practice to guide treatment planning with each patient.
timeFrame: conclusion of study
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Bernard Bochner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01722955: Pre-warmed Intravenous Fluids and Monitored Anesthesia Care
Official title: Effect of Pre-warmed Intravenous Fluids on the Early Outcomes After Ambulatory Surgery Under Monitored Anesthesia Care
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypothermia
Keywords: Prewarmed fluid
monitored anesthesia care
core body temperature
anesthetic satisfaction
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2012-11-07
Enrollment: 50
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of the study is to compare effect of pre-warmed intravenous fluids on the early outcomes in ambulatory patients undergoing monitored anesthesia care.

Detailed description: Monitored anesthesia care (MAC) has been increasing in fast track anesthesia for ambulatory or outpatient surgery. MAC provides lower anesthetic agents than general anesthesia, however it has been shown to result high anesthetic complication rate because of negligent monitoring. Therefore, aim of this study is to investigate the effect of pre-warmed intravenous fluids on the core body temperature and the early outcomes.

Eligibility criteria: Inclusion Criteria:

* 20years to 70years old female patients undergoing urinary incontinence surgery under monitored anesthesia care.

Exclusion Criteria:

* Preoperative tympanic membrane temperature \>38 or \< 36
* End stage heart failure or renal failure
* Otitis media

Primary outcomes:
measure: Tympanic membrane temperature
timeFrame: 30min after anesthetic induction
Secondary outcomes:
measure: Postoperative chilling and shivering
timeFrame: on arrival at the postanesthetic care unit ( 1hour after the anesthetic induction)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung medical center
Study officials:
affiliation: Samsung MC
name: Myung Hee Kim, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yokoyama K, Suzuki M, Shimada Y, Matsushima T, Bito H, Sakamoto A. Effect of administration of pre-warmed intravenous fluids on the frequency of hypothermia following spinal anesthesia for Cesarean delivery. J Clin Anesth. 2009 Jun;21(4):242-8. doi: 10.1016/j.jclinane.2008.12.010. Epub 2009 Jun 6.
Clinical trial NCT05868655: The Effect of Exercise on Amateur American Football Players
Official title: The Effect of Exercise on Amateur American Football Players
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Athletic Injuries
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2023-05-22
Enrollment: 43
Sex: MALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prior to and following the eight-week application, evaluation was conducted.
Primary purpose: TREATMENT

Brief summary: Football is a team activity that calls for numerous sophisticated talents, including speed, endurance, speed, strength, and quickness. It is getting more and more popular among professional and amateur players, particularly in America.

Detailed description: Current research demonstrates that characteristics of American football players like body composition, sprint performance, metabolism, and strength are influenced by elements like the league played, training history, and position played. The ability to generate power with both the upper and lower bodies, change direction quickly, accelerate quickly in both positive and negative directions, run quickly, engage in high-intensity collisions repeatedly, and maintain muscular strength endurance are all skills that players on the court may need.

Eligibility criteria: Inclusion Criteria:

* Male individuals between the ages of 18-25
* Being an American football player
* Regular attendance at training sessions

Exclusion Criteria:

* Known neurological disorder
* Serious orthopedic disorders that will prevent him from exercising
* cognitive impairment

Primary outcomes:
measure: The Tampa Kinesiophobia Scale
timeFrame: 8 weeks
measure: Optojump
timeFrame: 8 weeks
measure: The duration of the jump (milliseconds) .(Optojump)
timeFrame: 8 weeks
measure: The Biodex balance system
timeFrame: six weeks
Secondary outcomes:
measure: Sit-Reach Test
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: HAZAL genç
state: None Selected
Study officials:
References:
citation: Fullagar HHK, McCunn R, Murray A. Updated Review of the Applied Physiology of American College Football: Physical Demands, Strength and Conditioning, Nutrition, and Injury Characteristics of America's Favorite Game. Int J Sports Physiol Perform. 2017 Nov 1;12(10):1396-1403. doi: 10.1123/ijspp.2016-0783. Epub 2017 Dec 19.
Clinical trial NCT06756555: Effect of Incentive Spirometry on Post-operative Pulmonary Complications After Bariatric Surgery
Official title: Effect of Incentive Spirometry on Post Operative Pulmonary Complications After Bariatric Surgery: a Cross Sectional Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Bariatric Surgery Candidate
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2025-01-03
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: population included Complications After Bariatric Surgery to check the Effects of Incentive Spirometry on Post-operative Pulmonary

Brief summary: Today, obesity is the major concern and obese patients are at higher risk of developing pulmonary complications. Incentive Spirometry is widely used worldwide to reduce rates of pulmonary complications. In this study, Effect of Incentive Spirometry (IS) on Post Operative Bariatric Patients (Male and Female) will be studied on patients about sample size of 140 including male and female gender, BMI above 30 kg/m2 having Post Operative Bariatric Surgeries with chances of generating Pulmonary complications.

Detailed description: Research will be conducted in Shalamar Hospital Lahore and data will be collected through predesigned proforma. In previous studies some studies show positive and but some studies don't recommend Incentive Spirometry as a post operative Rehabilitation therapy.But this therapy device is still used in present days in Post Operative patients to prevent pulmonary complications. In this study we conclude the positive or negative effect of Incentive Spirometry.

Eligibility criteria: Inclusion Criteria:

* Patient having weight above 25 BMI
* Age between 18 years to 60 years
* having Post Operative pulmonary complication.
* Bariatric patients (Sleeve gastrectomy,Mini gastric Bypass,Sleeve gastrectomy to gastric bypass ,sleeve re do surgery)..

Exclusion Criteria:

* Patients weight below 25BMI.
* other abdominal surgeries.
* Patients having absence of teeth.
* Patients age below 18 years .

Primary outcomes:
measure: Respiratory rate using Spirometry
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Shalamar Hospital Mughalpura
state: Punjab
Study officials:
References:
Clinical trial NCT02645955: Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis E Virus Infection
Lead sponsor: Xiamen University
Sponsor class: OTHER
First posted: 2016-01-05
Enrollment: 436
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 200 each for the MHD patient group and the control group

Brief summary: Primary Purpose:

1. Evaluate the prevalence and incidence of HEV infection in MHD patients.
2. Compare differences of the prevalence and incidence between the MHD patients and the control. .

Secondary purpose:

Analyze risk factors of HEV infection.

Detailed description: This is an Epidemiological study manufactured by Xiamen University. The primary purpose of this study is to evaluate the prevalence and incidence of HEV infection in MHD patients and to compare differences between the MHD patients and the control. The secondary purpose of this study is to analyze risk factors of the infection of HEV. There are two phases in this study. The first phase is a cross-sectional study. Approximately 200 MHD patients will be enrolled in MHD patient group, followed by control group's enrollment according to the age and gender of the MHD patient group. Blood samples and questionnaire were got at this time. Secondly, 100 enrolled volunteers in each group who is negative for HEV-IgM、HEV-IgG、HEV RNA will be introduced into the cohort study. The MHD patient group will been taken blood samples at an interval of 3 month until the 12th month after the first phase, however, the control group only need one blood sample at 12th month.

Eligibility criteria: Inclusion Criteria:

* Maintenance hemodialysis patients and healthy people as control
* Can understand the study progress, willing to sign the informed consent and participate the study

Exclusion Criteria:

* Has received HEV vaccines

Primary outcomes:
measure: prevalence of HEV infection
timeFrame: up to 1 year after enrollment
measure: new-infection rate of HEV infection
timeFrame: up to 1 year after enrollment
Secondary outcomes:
measure: risk factors of HEV infection
timeFrame: up to 1 year after enrollment
Other outcomes:
Locations:
Study officials:
affiliation: Zhongshan Hospital Xiamen University
name: Jianjun Niu, M.Sc.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02905955: Vacuumtherapy After Venous Hybrid Procedures
Official title: Negative Pressure Wound Management (NPWT) System for Inguinal Wounds After Venous Hybrid Procedures
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Wound Infection
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2016-09-19
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: All patients with deep venous obstruction below the sapheno-femoral junction elective for hybrid procedure with creation of an arterio venous-fistula (AVF) in the MUMC or patients with primary percutaneous procedure (and thus venous obstruction above the sapheno-femoral junction) who present with occluded stents which need an additional AVF after thrombolysis will receive a Prevena NPWT. Incidence of wound infections and wound scoring will be performed afterwards.


Eligibility criteria: Inclusion Criteria:

* All patients with deep venous obstruction below the sapheno-femoral junction primary elective for hybrid procedure with creation of an AV-fistula in the MUMC
* Be able to communicate in Dutch
* Life expectancy \>1 year

Exclusion Criteria:

* Patients with allergies for the components of the used negative pressure incision management system (Prevena)

Primary outcomes:
measure: Number of Patients With wound infections or Adverse Events That Are Related to Prevena incision management negative pressure wound therapy
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Centre
state: Limburg
Study officials:
affiliation: Maastricht University Medical Centre
name: J. Laanen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04350255: A Register Based Prospective Study During Implementation of a New Cup
Official title: STEISURE - Trident II - A Registerbased Multicentric Prospective Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Prospective
Keywords: Hip arthroplasty
Implant survival
Clinical outcome
X-ray
Implant Migration
Patient reported outcomes
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
Collaborators: name: Stryker Nordic
First posted: 2020-04-17
Enrollment: 500
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In a prospective register-based study, we aim to evaluate the implant survival, clinical outcomes and X-ray findings by following a cohort of patients operated with the Trident II cup.

Detailed description: Data will be collected from a cohort consisting of minimum 500 total hip arthroplasties. The patients will be recruited from multiple high volume centers in Sweden. To determine if there is evidence of inferiority as per benchmarking recommendations by The Orthopaedic Data Evaluation Panel the following parameters will be studied: Clinical parameters such as EQ-5D, Oxford Hip Score and Forgotten Joint Score, preoperative and after 1, 3, 6 and 10 years. Conventional radiography will be done preoperatively, postoperatively, 3, 6 and 10 years after total hip replacement. CTMA will be done postoperatively, 3 and 6 month and 2 years after total hip replacement.

Eligibility criteria: Inclusion Criteria:

* Primary hip replacement
* Eligible for uncemented fixation of the acetabular component
* Suitable for one of the stem designs from Stryker Orthopaedics
* Accepts follow-up according to the study protocol

Exclusion Criteria:

* Difficulties to understand written information due to language problems or other reasons
* Use of augments needed
* Acute hip fracture
* Tumor in the hip joint

Primary outcomes:
measure: Implant survival at 3 years
timeFrame: 3 years
Secondary outcomes:
measure: Implant migration measured with Computer Tomography Microanalysis in a subcohort of patients motion Analysis (CTMA) in a sub-cohort of patients
timeFrame: CTMA will be done postoperatively, 3 month and 6 months and 2 years after total hip replacement
measure: Implant survival at 10 years
timeFrame: 10 years
measure: EQ-5D
timeFrame: 10 years
measure: Plain radiographs in a sub-cohort of patients
timeFrame: 10 years
measure: Adverse events using the national patient register
timeFrame: 10 years
measure: Adverse events using the regional VEGA database
timeFrame: 10 years
measure: Oxford Hip Score
timeFrame: 10 years
measure: Forgotten Joint Score
timeFrame: 10 years
Other outcomes:
Locations:
city: Molndal
country: Sweden
facility: Department of Orthopaedics
state: Västra Götaland
Study officials:
References:
Clinical trial NCT00978055: Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)
Official title: Single-Dose Fasting Bioequivalence Study of Liothyronine Sodium Tablets (50 Mcg; Mylan) to Cytomel® Tablets (50 Mcg; King) in Healthy Euthyroid Adult Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: MylanPharma
Sponsor class: UNKNOWN
First posted: 2009-09-16
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The objective of this study was to investigate the bioequivalence of Mylan's liothyronine sodium 50 mcg tablets to King's Cytomel® 50 mcg tablets following a single, oral 100 mcg (2 x 50 mcg) dose administration under fasting conditions.


Eligibility criteria: Inclusion Criteria:

* healthy males and/or non-pregnant, non-lactating females, 18 years and older
* able to swallow medication

Exclusion Criteria:

* institutionalized subjects
* history of any significant disease
* use of any prescription or OTC medications within 14 days prior to start of study
* received any investigational products within 30 days prior to start of study

Primary outcomes:
measure: Bioequivalence
timeFrame: within 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Fargo
country: United States
facility: PRACS Institute, Ltd.
state: North Dakota
Study officials:
References:
Clinical trial NCT01037855: Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine
Official title: A Prospective Observational Study of Safety and Occurrence of Influenza-like Illness Following Administration of Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine Celtura
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Novel Influenza A (H1N1)
A New Flu Virus of Swine Origin
Keywords: Swine Flu H1N1 vaccine
Adjuvanted flu cell culture derived
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2009-12-23
Enrollment: 4028
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: population of children, adolescents, adults and elderly

Brief summary: This is an observational study of safety and occurrence of influenza-like illness following administration of flu cell culture derived adjuvanted swine origin A (H1N1) pandemic subunit vaccine in subjects 6 months of age and older.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 6 months
* Subjects will be vaccinated with Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine, independently of this study.
* Subjects or parent/guardian willing to provide informed consent prior to vaccination administration and complete all of the study, including follow-up contact

Exclusion Criteria:

• Received any prior H1N1 vaccination

Primary outcomes:
measure: To quantify the safety of Flu Cell Culture Derived Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine in actively monitored subjects
timeFrame: 6 months
measure: To characterize the incidence of AEs in specific age groups following an active surveillance of vaccinated subjects
timeFrame: 6 months
Secondary outcomes:
measure: To assess the occurrence of laboratory confirmed H1N1sw and influenza-like illness following vaccination
timeFrame: 6 Months
Other outcomes:
Locations:
city: Av. Santa Maria
country: Chile
facility: Clinica Indisa
state: Santiago
city: Bogota
country: Colombia
facility: Fundación Universitaria de Ciencias de Salud- Hospital San José Calle
city: Calle 66 # 40-07 - Bogotá
country: Colombia
facility: Nueva EPS: Centro de Especialistas Barrios Unidos - MEDERI
city: Calle 9 No. 24-37 - Yopal, Casanare
country: Colombia
facility: Hospital local de Yopal E.S.E
city: Carrera 16 No. 82-57 Bogotá
country: Colombia
facility: Clinica del Country
city: Carrera 52 No. 67A-71 - Barrios Unidos - Bogotá
country: Colombia
facility: Hospital Universitario Infantil San José
city: Cra. 42 A No. 17-50
country: Colombia
facility: CAIMED - Centro de Atencion e Investigación Medica
city: Augustenburger Platz 1
country: Germany
state: Berlin
city: Rue du Bugnon 44
country: Switzerland
facility: Policlinique Médicale Universitaire
state: CH-1011 Lausanne
city: Hirschengraben 84
country: Switzerland
facility: Institute of Social and Preventive Medicine, Division of Communicable Diseases
state: CH-8001 Zürich
Study officials:
References: